Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

ute leukemia, a currently incurable blood cancer. L-Annamycin is currently in a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia, and in a Phase I clinical trial in children and young adults with refractory or relapsed acute lymphocytic leukemia or acute myelogenous leukemia. L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has a proprietary drug Guanilib in preclinical development for gastro- intestinal disorders. Callisto has exclusive worldwide licenses from Genzyme Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at http://www.callistopharma.com.

Forward-Looking Statements

Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Annual Report on Form 10-K for the year ended December 31, 2006, and other periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promi
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... ANAHEIM, Calif. , July 14, 2014  Mallinckrodt ... (NASDAQ: QCOR ) today announced that the registration ... Exchange Commission ("SEC") by Mallinckrodt plc on May 16, 2014 ... proxy statement of Mallinckrodt and Questcor that also constitutes a ... The registration statement on Form S-4 is available on the ...
(Date:7/14/2014)... BEIJING , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... China , announced today that it will hold its 2014 ... Beijing Time. The meeting will be held at No. 39 Shangdi Xi ... record as of July 9, 2014 will be eligible to vote and ... is to approve the re-election of Weidong Yin , Yuk ...
(Date:7/14/2014)... and LONDON , July 14, 2014 ... IXICO plc (AIM: IXI) jointly announced today the formation ... companies. Dr. Edward Ashton , Ph.D., chief scientific ... have seven members. "The formation of this ... the international commercial and operational alliance we signed with ...
Breaking Medicine Technology:Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 2Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 3Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 4Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 5Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 6Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction 7Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9
... by genomics, SAN DIEGO, April 14 ... Therapeutics, Inc. (CTI) (Nasdaq,and MTAX: CTIC), presented data ... patients more likely to respond to treatment with ... for,Cancer Research (AACR) annual meeting. These findings will ...
... April 13 Researchers from the,Barbara Ann ... findings,showing that adding curcumin or resveratrol to ... growth of chemo-resistant colon cancer,cells. The poster ... Cancer Research (AACR) Annual Meeting in San ...
Cached Medicine Technology:New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 2New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 3New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 4New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 5Karmanos Researchers Find Non-Toxic Agents Added to Conventional Chemotherapy Decrease Survival of Colon Cancer Cells 2
(Date:7/14/2014)... to a new market research report "Power Electronics Market ... (Power IC, Power Module & Power Discrete), Applications, and ... the Power Electronics market is expected to boom in ... at $36.86 Billion and expected to grow at a ... includes an in-depth analysis of the applications and geography. ...
(Date:7/14/2014)... July 14, 2014 This report ... market in Americas. The analysis includes market size ... period and key company share data by revenue ... Brazil and Mexico. It uses data and information ... and in-house analysis. , Scope, ...
(Date:7/14/2014)... (HealthDay News) -- Along with improving vision, cataract surgery ... and other types of dementia, a new study suggests. ... the researchers said. "These preliminary results indicate that ... people with dementia and their loved ones, both visual ... Reserve University and University Hospitals Case Medical Center, in ...
(Date:7/14/2014)... By Kathleen Doheny ... -- Losing a spouse may be linked to multiple health ... new study. For certain seniors, widowhood may even delay ... mild memory problem, losing the spouse was associated with a ... stayed married," said study researcher Dr. Bryan Woodruff. ...
(Date:7/14/2014)... T.E.N., an information technology and security ... nominations will be accepted now through Sept. 12, ... North America Awards. , Awards include the ... executives who have made a positive impact on ... compliance, privacy and information security; and the ISE® ...
Breaking Medicine News(10 mins):Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 2Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 3Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 4Health News:Power Electronics Market Estimated to Reach $36.86 Billion by 2020 at CAGR of 7.74% - New Report by MarketsandMarkets 5Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Cataract Surgery a Plus for Someone With Dementia, Study Says 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... cholesterol level in blood.,High level of cholesterol, which is ... can lead to serious health risks. ,// ,Researchers ... examined 199 healthy middle-aged men and women to know ... can increase cholesterol and heighten cardiovascular risk, reports Newswise ...
... of bird flu, even as the government has given approval ... ,The latest outbreaks of the deadly H5N1 strain of ... southwestern province of Yunnan and the northwestern region of Ningxia, ... birds died in Yunnan's Chuxiong district Thursday, and 230 died ...
... is planning expansion of its super-speciality hospital chain with ... Kolkata and Bangalore.// ,"We have embarked on the ... Delhi) which would be ready by 2007-end. We also ... the chain's vice president, told IANS., ,Unlike the ...
... more than 1,200 children, whose organs were removed after death ... average of about ?2,900 in a compensation deal announced recently ... the apex body had fought the cases involving organ-retention ... to a total figure of around ?3.6 million for the ...
... people could be putting their health at risk by ... and other health professionals.// ,The survey of more ... Health Professions Council (HPC), found that about 81% of ... professional were oblivious to whether they were properly qualified ...
... juice has anti-bacterial properties? It has now been found ... compounds that can help preserve dental health by prevention ... University of Rochester Medical Center have been credited with ... acts just similar to a Teflon sheath, commonly used ...
Cached Medicine News:Health News:Wockhardt Group Plans Hospital In Delhi By End-2007 2Health News:Organ Scandals Compensation And The Aftermath 2Health News:Credentials Of Specialists Need To Be Checked 2Health News:Cranberry juice to Prevent Dental Decay 2
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
... determination of Estradiol (E2) concentration in human serum ... hormone with a phenolic A ring. This ... It is the most potent natural Estrogen, ... smaller amounts by the adrenal cortex, and the ...
... is the most potent, naturally secreted estrogen ... the ovary [1]. In the ovary, estradiol ... estrone, a less potent estrogen derived from ... many body tissues. In men, small amounts ...
... VITROS ECi brings true automation and ... testing. Highly sensitive assays for thyroid, ... bone metabolism testing are currently available, ... The VITROS ECi can simultaneously process ...
Medicine Products: